This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (173)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jonathan T. Edelson, MD; Milton C. Weinstein, PhD; Anna N. A. Tosteson, ScD; Larry Williams, MSc; Thomas H. Lee, MD; Lee Goldman, MD, MPH

JAMA. 1990;263(3):407-413.

Abstract
To evaluate the comparative efficacy and cost-effectiveness of various antihypertensive medications in persons aged 35 through 64 years with diastolic blood pressure of 95 mm Hg or greater and no known coronary heart disease, we used the Coronary Heart Disease Policy Model, which is a computer simulation of overall mortality as well as the mortality, morbidity, and cost of coronary heart disease in the US population. From the pooled literature, we estimated the antihypertensive and total cholesterol effects of various antihypertensive regimens. For 20 years of simulated therapy from 1990 through 2010, the cost per year of life saved was projected to be $10 900 for propranolol hydrochloride; $16 400 for hydrochlorothiazide; $31 600 for nifedipine; $61 900 for prazosin hydrochloride; and $72 100 for captopril. Doubling the cholesterol effects of the agents under study did not significantly change their effectiveness because, in general, lowering diastolic blood pressure by 1 mm Hg was equivalent to lowering the cholesterol level by 6%. Although any projection requires multiple estimates, each of which may be open to debate, propranolol appears to be the preferred initial option under most of a variety of alternative assumptions.

(JAMA. 1990;263:408-413)

Author Affiliations
From the Divisions of Clinical Epidemiology (Drs Edelson, Tosteson. Lee, and Goldman and Mr Williams) and General Medicine (Drs Edelson, Lee, and Goldman), Consolidated Department of Medicine, Brigham and Women's and Beth Israel hospitals and Harvard Medical School; and the Department of Health Policy and Management, Harvard School of Public Health (Dr Weinstein), Boston, Mass. Dr Edelson is now with Medical Decision Resources, Brookline, Mass.

Footnotes
Reprint requests to Division of Clinical Epidemiology, Consolidated Department of Medicine, Brigham and Women's and Beth Israel hospitals, 75 Francis St, Boston, MA 02115 (Dr Goldman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Preventing Chronic Disease: An Important Investment, But Don't Count On Cost Savings
Russell
Health Aff (Millwood) 2009;28:42-45.
ABSTRACT | FULL TEXT  

Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure
Gohler et al.
Eur J Heart Fail 2008;10:1026-1032.
ABSTRACT | FULL TEXT  

Review: Hypertension, a health economics perspective
Alcocer and Cueto
Ther Adv Cardiovasc Dis 2008;2:147-155.
ABSTRACT  

Toward Targeted Hypertension Screening Guidelines
van Buuren et al.
Med Decis Making 2006;26:145-153.
ABSTRACT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it?
Krumholz et al.
J Am Coll Cardiol 2002;40:603-615.
FULL TEXT  

Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients
Elliott et al.
Arch Intern Med 2000;160:1277-1283.
ABSTRACT | FULL TEXT  

Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Hillner et al.
JCO 2000;18:72-72.
ABSTRACT | FULL TEXT  

Cross-classification of JNC VI Blood Pressure Stages and Risk Groups in the Framingham Heart Study
Lloyd-Jones et al.
Arch Intern Med 1999;159:2206-2212.
ABSTRACT | FULL TEXT  

High-Priced Technology Can Be Good Value for Money
Weinstein
ANN INTERN MED 1999;130:857-858.
FULL TEXT  

The Costs and Cost-Effectiveness of Unrelated Donor Bone Marrow Transplantation for Chronic Phase Chronic Myelogenous Leukemia
Lee et al.
Blood 1998;92:4047-4052.
ABSTRACT | FULL TEXT  

Prevention and Medicare Costs
Russell
NEJM 1998;339:1158-1160.
FULL TEXT  

Bethesda conference: conference for the design of clinical trials to study circulatory support devices for chronic heart failure
Pae et al.
Ann. Thorac. Surg. 1998;66:1452-1465.
FULL TEXT  

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
UK Prospective Diabetes Study Group
BMJ 1998;317:720-726.
ABSTRACT | FULL TEXT  

The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Arch Intern Med 1997;157:2413-2446.
ABSTRACT  

Aspirin and Coronary Disease
Vogel and Handin
NEJM 1996;335:1161-1162.
FULL TEXT  

A 76-Year-Old Woman Considering Total Hip Replacement
Callaghan
JAMA 1996;276:486-491.
ABSTRACT  

A Cost-effectiveness Analysis of Total Hip Arthroplasty for Osteoarthritis of the Hip
Chang et al.
JAMA 1996;275:858-865.
ABSTRACT  

Use of Antihypertensive Drugs and Trends in Blood Pressure in the Elderly
Glynn et al.
Arch Intern Med 1995;155:1855-1860.
ABSTRACT  

Trends in Medication Choices for Hypertension in the Elderly : The Decline of the Thiazides
Monane et al.
Hypertension 1995;25:1045-1051.
ABSTRACT | FULL TEXT  

The Cost-effectiveness of HMG-CoA Reductase Inhibitors to Prevent Coronary Heart Disease: Estimating the Benefits of Increasing HDL-C
Hamilton et al.
JAMA 1995;273:1032-1038.
ABSTRACT  

Management of Childhood Lead Poisoning: Clinical Impact and Cost-Effectiveness
Glotzer et al.
Med Decis Making 1995;15:13-23.
ABSTRACT  

Cost and Outcome of Intensive Care for Patients With AIDS, Pneumocystis carinii Pneumonia, and Severe Respiratory Failure
Wachter et al.
JAMA 1995;273:230-235.
ABSTRACT  

A Cost Analysis of Topical Drug Regimens for Dermatophyte Infections
Chren and Landefeld
JAMA 1994;272:1922-1925.
ABSTRACT  

The Impact of Age on the Cost - Effectiveness of Hypertension Treatment: An Analysis of Randomized Drug Trials
Johannesson
Med Decis Making 1994;14:236-244.
ABSTRACT  

Costs and Effectiveness of Angiotensin Converting Enzyme Inhibition in Patients With Congestive Heart Failure
Paul et al.
Arch Intern Med 1994;154:1143-1149.
ABSTRACT  

Setting Limits in Clinical Medicine
Murphy et al.
Arch Intern Med 1994;154:505-512.
ABSTRACT  

Which Hat Do I Wear?
Smith
JAMA 1993;270:1657-1659.
 

Reducing Health Care Costs by Reducing the Need and Demand for Medical Services
Fries et al.
NEJM 1993;329:321-325.
FULL TEXT  

The Role of Prevention in Health Reform
Russell
NEJM 1993;329:352-354.
FULL TEXT  

Quality of Life and Antihypertensive Therapy in Men -- A Comparison of Captopril with Enalapril
Testa et al.
NEJM 1993;328:907-913.
ABSTRACT | FULL TEXT  

Intensive Care, Survival, and Expense of Treating Critically III Cancer Patients
Schapira et al.
JAMA 1993;269:783-786.
ABSTRACT  

Application of an Algorithm for Staging Small-cell Lung Cancer Can Save One Third of the Initial Evaluation Costs
Richardson et al.
Arch Intern Med 1993;153:329-337.
ABSTRACT  

Breast Cancer Screening for Elderly Women with and without Comorbid Conditions: A Decision Analysis Model
Mandelblatt et al.
ANN INTERN MED 1992;116:722-730.
ABSTRACT  

Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer: Estimates Using Decision Analysis While Awaiting Clinical Trial Results
Hillner et al.
JAMA 1992;267:2055-2061.
ABSTRACT  

{beta}-Blockers and Depression: Evidence Against an Association
Bright and Everitt
JAMA 1992;267:1783-1787.
ABSTRACT  

Who Really Determines Your Patients' Prescriptions?
Moser et al.
JAMA 1991;265:498-500.
ABSTRACT  

The Cost-effectiveness of Antihypertensive Drugs
Kaplan
JAMA 1990;263:2888-2889.
ABSTRACT  

Screening for Hypertension
De Nino and Mulrow
ANN INTERN MED 1990;112:796-797.
ABSTRACT  

PROPRANOLOL: THE MOST COST-EFFECTIVE ANTIHYPERTENSIVE
JWatch General 1990;1990:3-3.
FULL TEXT